RE:Phase 3 clinical trial costs for small molecule oncology druA 2019 Italian Phase 3 costing study to assess the estimated “per patient” total cost per single Oncologic Italian Cancer Center participating in a multicenter clinical trial with new anticancer biological agents using the activity-based costing (ABC) methodology found that on average, a trial with immunotherapy drugs accounts for 12.659 Euro per patient, namely 2.302 Euro more than a clinical trial with target based agents.
The study authors analyzed nine randomized phase 3 clinical trials with new anticancer biological agents carried out at the Thoracic, Melanoma, and Uro-Gynecological Medical Oncology of the National Cancer Institute of Napoli, Italy in order to indentify “per patient” costs.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210330